Mecasermin - Cephalon

Drug Profile

Mecasermin - Cephalon

Alternative Names: CEP 120; IGF-1 - Cephalon; Insulin-like growth factor-1 - Cephalon; KW 6151; Myotrophin; Recombinant human insulin-like growth factor-1; Somatomedin-1 - Cephalon

Latest Information Update: 26 Oct 2011

Price : $50

At a glance

  • Originator Cephalon
  • Developer Cephalon; Kyowa Hakko; Merck & Co
  • Class Antihyperglycaemics; Growth factors; Peptides
  • Mechanism of Action Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Multiple sclerosis; Peripheral nervous system diseases; Renal failure

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 18 Sep 2001 Discontinued-III for Amyotrophic lateral sclerosis in Japan (Unknown route)
  • 18 Sep 2001 Suspended - Preregistration for Amyotrophic lateral sclerosis in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top